275 WYMAN STREET, WALTHAM, MA
News, Material Contracts
Reports Recent Business Highlights and Second Quarter 2025 Financial Results
Cogent Biosciences Reports Positive Results from SUMMIT Trial of Bezuclastinib
Other Events
Secures up to $400 Million in Non-Dilutive Financing
Investor Presentation
Reports First Quarter 2025 Financial Results
Annual Report to Security Holders
Q2
Q1
FY 2023
Q3
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
PRE 14A
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Post-Effective Amendment to Registration Statement